Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¿äÆó°¡ µ¿¹ÝµÈ ¼ö¼ú °íÀ§Çè Àü¸³¼±ºñ´ëÁõ ȯÀÚ¿¡¼­ÀÇ °æ¿äµµ±ØÃÊ´ÜÆÄ¿­Ä¡·á¹ýÀÇ ¿ªÇÒ Role of Transurethral Microwave Thermotherapy for Urinary Retention due to Benign Prostatic Hyperplasia in High-Risk Surgical Patients

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 4È£ p.369 ~ 373
Á¶½Â·¡, À̱¤¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¶½Â·¡ (  ) 
¼­¿ïÀû½ÊÀÚº´¿ø ºñ´¢°ú

À̱¤¼ö (  ) 
¼­¿ïÀû½ÊÀÚº´¿ø ºñ´¢°ú

Abstract

¼­·Ð
Àü¸³¼±ºñ´ëÁõ ȯÀÚ¿¡¼­ ±Þ¼º¿äÆó°¡ ¿Ã È®·üÀº ¾à10%ÀÌ¸ç ±× ±âÀüÀº Àü¸³¼±°æ»ö¿¡ ±âÀÎÇÑ
´Ù´Â °ÍÀÌ °¡Àå ½Å·Ú ÇÒ¸¸ÇÑ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ·¯ÇÑ È¯ÀÚ´Â ±×¿¡ ÀÇÇÑ ¿ä·Î°¨¿°, ¼ö½Å
Áõ, ¿äµ¶Áõ µîÀÌ ¹ß»ýÇÒ ¼ö ÀÖ°í, Foley Ä«Å×ÅÍ À¯Ä¡ ÈÄ ¹è´¢°¡ °¡´ÉÇÏ´õ¶óµµ ´Ù½Ã ±Þ¼º¿äÆó
°¡ ³ªÅ¸³¯ È®·üÀº 1ÁÖ³» 70%,3 ±×¸® °í 1³â ³»¿¡´Â 90%·Î ¹ßÇ¥µÇ¾î ÀÖ´Ù. µû¶ó¼­ ¿äÆó¸¦
º¸ÀÌ´Â Àü¸³¼±ºñ´ëÁõ ȯÀÚ´Â ÀÀ±Þóġ¿Í °æ¿äµµÀü¸³¼±ÀýÁ¦¼ú µî ¼ö¼ú¿ä¹ýÀÌ ÇÊ¿äÇÑ °ÍÀ¸·Î
µÇ¾î ÀÖ´Ù.
±×·¯³ª Àü½ÅÀÌ Çã¾àÇÑ È¯ÀÚ ¶Ç´Â ³»°úÀû ±âÀúÁúȯÀÌ ÀÖ´Â °æ¿ì ¸¶Ãë¿Í ¼ö¼úÀÌ Á¦ÇÑÀ» ¹Þ
´Â °æ¿ì°¡ ÀÚÁÖ ¹ß»ýÇϸç, ¼ö¼ú¿¡ ÀÇÇÑ ÃâÇ÷, °¨¿°, ¿ªÇ༺»çÁ¤, ¹ß±âÀå¾Ö, ¿ä½Ç±Ý, ¿äµµÇùÂø
µî ÇÕº´Áõ ¶ÇÇÑ µå¹°Áö ¾Ê°Ô ¹ß»ýÇÑ´Ù. ±×¿¡ µû¶ó Áö³­ 10³â°£ ¸¹Àº ºñħ½ÀÀû Ä¡·á¹æ¹ýµéÀÌ
°³¹ßµÇ¾î ȯÀÚ³ª ÀÇ»ç ¸ðµÎ¿¡°Ô ¼±ÅÃÀÇ ÆøÀÌ ³Ð¾îÁ³À¸¸ç, ƯÈ÷ ¸¶Ãë½Ã³ª °æ¿äµµ Àü¸³¼±ÀýÁ¦
¼úÈÄ ½ÉÀåÀÇ ÇÕº´ÁõÀ» ÃÊ·¡ÇÒ °¡´É¼ºÀÌ ¸¹Àº ȯÀÚ¿¡°Ô´Â ¸Å¿ì À¯¿ëÇÏ°Ô Àû¿ëÇÒ ¼ö ÀÖ°Ô µÇ
¾ú´Ù. º»¿ø¿¡¼­´Â ºñ¼ö¼úÀû ¿ä¹ýÀÇ ÇϳªÀÎ °æ¿äµµ±ØÃÊ´ÜÆÄÀü¸³¼±¿­Ä¡·á¹ý(TUMT;
transurethral microwave thermotherapy)À» ÀÌ¿ëÇÏ¿© ¿äÆóȯÀÚ¸¦ ´ë»óÀ¸·Î ½ÃÇàÇÑ °á°ú¸¦
°ËÅäÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : To evaluate the outcome of transurethral microwave thermotherapy(TUMT)
for the treatment of urinary retention due to benign prostatic hyperplasia(BPH) in the
high-risk surgical patients.
Materials and Methods : From November, 1992 to March, 1997, a total of 26 patients
with urinary retention due to BPH underwent TUMT with PRIMUS U £« R because of
poor physical and medical status at the department of urology, Red Cross hospital in
Seoul. Mean patient age was 73years(range 58 to 97years), mean prostatic weight was
35gm(range 14gm to 68gm) and mean duration of retention was 1.7 months(range 1 day
to 36months). The once or twice 1-hour TUMT session was well tolerated and without
significant adverse effect. Patients were divided into responder and non-responder. In
responder group who were catheter free after TUMT, peak flow rate and post-void
residual urine(PVR) were assessed at 3, or 6, or 12months of follow-up.
Results : Of 26 patients, 16 patients were responders(61.5%) after TUMT for the
duration of follow-up. The mean peak flow rate and post-voiding residual urine during
12months of follow-up period were 10.4m1/sec(range 3 to 22m1/sec) and 62.8ml(range 0
to 269m1), respectively. There was no major complication.
Conclusions : From these results TUMT appears to be safe and erective treatment
modality in the high-risk surgical patients.

Transurethral microwave thermotherapy; Benign prostatic hyperplasia; Urinary retention; High-risk surgical patients;

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS